Trial Profile

A Phase II Study Combining Pembrolizumab With Olaparib in Metastatic Pancreatic Adenocarcinoma (PDA) Patients With High Tumour Mutation Burden

Status: Not yet recruiting

Phase of Trial: Phase II

Latest Information Update: 02 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Olaparib (Primary) ; Pembrolizumab (Primary)
Indications Adenocarcinoma; Pancreatic cancer
Focus Therapeutic Use

Most Recent Events

02 Aug 2024 Last checked against ClinicalTrials.gov: US National Institutes of Health.
01 Jul 2024 Planned End Date changed from 4 May 2026 to 1 Jan 2028.
01 Jul 2024 Planned primary completion date changed from 31 Dec 2025 to 31 Jul 2027.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com